Mivacurium (chloride)

Mivacurium is an antagonist of nicotinic acetylcholine receptors (nAChRs) and muscarinic M2 and M3 receptors (ED50s = 0.08, 0.3, and 0.1 mg/kg for ex vivo human skeletal muscle nAChRs, guinea pig cardiac M2 receptors, and guinea pig bronchial M3 receptors, respectively). It inhibits acetylcholine-induced activation of neuronal nAChRs (IC50s = 69.04, 3.71, 1.52, and 2.90 for human alpha3beta2-, alpha3beta4-, alpha4beta2-, and alpha7-containing nAChRs expressed in Xenopus oocytes). Mivacurium also inhibits adult human muscular alpha1beta1epsilondelta-containing nAChRs (IC50 = 3.69 nM in Xenopus oocytes expressing the human recombinant receptor). In vivo, mivacurium inhibits bradycardia and bronchoconstriction induced by vagal stimulation or acetylcholine in guinea pigs. It also induces neuromuscular blockade (ED95 = 80 µg/kg) in sheep with a more rapid onset time than atracurium (Cay-17796) and vecuronium (Cay-15603). Formulations containing mivacurium have been used for pediatric anesthesia.Formal Name: (1R,1'R)-2,2'-[[(4E)-1,8-dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl] isoquinolinium, dichloride. CAS Number: 106861-44-3. Molecular Formula: C58H80N2O14 . 2Cl. Formula Weight: 1100.2. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Soluble, Water: Soluble. SMILES: O=C(OCCC[N+]1(C)CCC(C=C(OC)C(OC)=C2)=C2[C@H]1CC3=CC(OC)=C(OC)C(OC)=C3)CC/C=C/CCC(OCCC[N+]4(C)[C@H](CC5=CC(OC)=C(OC)C(OC)=C5)C(C=C(OC)C(OC)=C6)=C6CC4)=O.[Cl-].[Cl-]. InChi Code: InChI=1S/C58H80N2O14.2ClH/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10,,/h13-14,31-38,45-46H,15-30H2,1-12H3,2*1H/q+2,,/p-2/b14-13+,,/t45-,46-,59?,60?,,/m1../s1. InChi Key: WMSYWJSZGVOIJW-ONUALHDOSA-L.